By Tapan Panchal

LONDON--The U.K.'s competition regulator has imposed a 84.2 million pound ($107.18 million) fine on pharmaceutical company Pfizer Inc. (PFE) for charging the country's national health service excessively high prices for an anti-epilepsy drug.

The Competition and Markets Authority said Wednesday that Pfizer and drug distribution company Flynn Pharma broke competition law by charging excessive and unfair prices in the U.K. for phenytoin sodium capsules, an anti-epilepsy drug.

The regulator fined Flynn Pharma GBP5.2 million and has ordered both companies to reduce their prices.

-Write to Tapan Panchal at tapan.panchal@wsj.com

(END) Dow Jones Newswires

December 07, 2016 02:35 ET (07:35 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Pfizer Charts.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Pfizer Charts.